Skip to main content
Equibles

Martin Brenner

iBio, Inc. (IBIO)

Equibles does not estimate personal net worth.

Get an email with a short summary when iBio, Inc. publishes a filing, an earnings call transcript or a press release.

Get IBIO alerts

About Martin Brenner

iBio, Inc. reported in an 8-K filed December 2, 2022 that Martin Brenner was appointed Chief Scientific Officer (member of the office of the Chief Executive Officer), effective December 2, 2022. Martin Brenner has spoken on 4 investor events across 1 company, most recently for iBio, Inc. on November 10, 2026. iBio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at iBio, Inc. includes DR. MARTIN BRENNER (CEO and Board Member), Thomas F. Isett 3rd (CEO and Chairman), Chip Clark (Chairman) and 7 others.

“On December 2, 2022, during the interim period while the Company continues its search of a new Chief Executive Officer, the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.”
iBio, Inc. Form 8-K, filed December 2, 2022 · Read the filing

Martin Brenner on recent calls

“So our iVirus 610 program is an active in E antibody, so we're still, to this day, the only company with an antibody against the target. There's obviously liver knockdown pursued by multiple companies right now, but we feel like with an antibody we have a few points of differentiation against those.”
CEO, Guggenheim 3rd Annual Healthcare Innovation Conference ·
“So our iVirus 610 program is an active in E antibody, so we're still, to this day, the only company with an antibody against the target. There's obviously liver knockdown pursued by multiple companies right now, but we feel like with an antibody we have a few points of differentiation against those.”
CEO, Guggenheim Healthcare Innovation 2026 Conference ·
“I think we have a couple of other complex chronic diseases we can take as a playbook for obesity. right we have seen this before in type 2 diabetes in hypertension we're likely looking at a hyper segmentation of the market we're really not interested in treating obesity like a cosmetic disease we're really interested…”
CEO, Wells Fargo 21st Healthcare Conference ·
“I'll start with the pipeline, and I wanted to really kind of pause here for a second and explain what this really means. Obviously, our first molecule has just entered the clinic, which we have released this week.”
Other, Jefferies Global Healthcare Conference ·

Affiliation history

Company network

Leadership on record at iBio, Inc.

Recent activity